(Q36828410)

16 August 2017

1 reference

title

Sparfloxacin worldwide in vitro literature: isolate data available through 1994. (English)

1 reference

16 August 2017

M A Cohen

1

1 reference

16 August 2017

S L Yoder

series ordinal

2

1 reference

16 August 2017

G H Talbot

series ordinal

3

1 reference

16 August 2017

publication date

1 June 1996

1 reference

Diagnostic Microbiology and Infectious Disease

16 August 2017

published in

1 reference

16 August 2017

volume

25

1 reference

16 August 2017

issue

2

1 reference

16 August 2017

page(s)

53-64

1 reference

In vitro activity of sparfloxacin (AT-4140), a new quinolone agent, against invasive isolates from pediatric patients

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

High-level quinolone resistance amongst clinical isolates of Escherichia coli and Klebsiella pneumoniae from Spain.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

Increased activity of a new chlorofluoroquinolone, BAY y 3118, compared with activities of ciprofloxacin, sparfloxacin, and other antimicrobial agents against anaerobic bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

Emergent resistance to ciprofloxacin amongst Pseudomonas aeruginosa and Staphylococcus aureus: clinical significance and therapeutic approaches

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

CI-960 (PD127391 or AM-1091), sparfloxacin, WIN 57273, and isepamicin activity against clinical isolates of Mycobacterium avium-intracellularae complex, M. chelonae, and M. fortuitum

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

Antistaphylococcal activity of the fluoroquinolones CI-960, PD 131628, sparfloxacin, ofloxacin and ciprofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

Comparative in-vitro activities of the new quinolone, Bay y 3118, and ciprofloxacin, sparfioxacin, tosufloxacin, CI-960 and CI-990

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

Comparative activities of eight quinolones against members of the Bacteroides fragilis group

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

Incomplete cross-resistance between ciprofloxacin and sparfloxacin in staphylococci, with a note on selection pressure due to clinical use of ciprofloxacin.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

In vitro activity of sparfloxacin compared with those of five other quinolones

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

Antistaphylococcal activities of sparfloxacin (CI-978; AT-4140), ofloxacin, and ciprofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

Assessment of the bactericidal activity of sparfloxacin, ofloxacin, levofloxacin, and other fluoroquinolones compared with selected agents of proven efficacy against Listeria monocytogenes

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

In vitro activity of sparfloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

In vitro activity of sparfloxacin (CI-978, AT-4140, and PD 131501). A quinolone with high activity against gram-positive bacteria.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

In-vitro activity of sparfloxacin, a new quinolone antimicrobial agent

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

In-vitro susceptibility of Chlamydia pneumoniae (TWAR) to seven antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

Increasing resistance of Staphylococcus aureus to ciprofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

In-vitro activity of three new fluoroquinolones and synergy with ansamycins against Mycobacterium leprae

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

Comparative in vitro activity of the new quinolone sparfloxacin (CI-978, AT-4140) against nosocomial gram-negative bloodstream isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

In vitro activity of sparfloxacin (CI-978; AT-4140) for clinical Legionella isolates, pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

In vitro activity of sparfloxacin (AT-4140, CI-978, PD 131501), a new quinolone antimicrobial agent

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

Ciprofloxacin therapy of infections caused by Pseudomonas aeruginosa and other resistant bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

Activity of new quinolones against ciprofloxacin-resistant staphylococci

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

Comparative in vitro activities of 20 fluoroquinolones against Mycobacterium leprae

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

In vitro antimicrobial susceptibility of glycopeptide-resistant enterococci.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

In vitro activity of 79 antimicrobial agents against Corynebacterium group D2.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

Evaluation of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

Development of quinolone resistance and multiple antibiotic resistance in Salmonella bovismorbificans in a pancreatic abscess

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990, and WIN 57273 against anaerobic bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

In vitro activity of CP-99,219, a novel 7-(3-azabicyclo[3.1.0]hexyl) naphthyridone antimicrobial.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

Decreased susceptibility of Neisseria gonorrhoeae to ciprofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

Activities of newer fluoroquinolones against Shigella sonnei

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

In-vitro activity of sparfloxacin, pefloxacin, ciprofloxacin and temafloxacin against clinical isolates of Acinetobacter spp.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

Fluoroquinolone resistance an evolving national problem or just a problem for some physicians?

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

In vitro antimicrobial activity of sparfloxacin (AT-4140, CI-978, PD 131501) compared with numerous other quinolone compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

Susceptibility of Mycoplasma pneumoniae to several new quinolones, tetracycline, and erythromycin

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

In vitro and in vivo antichlamydial activities of newly developed quinolone antimicrobial agents

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

Inhibition of Legionella pneumophila in guinea pig peritoneal macrophages by new quinolone, macrolide and other antimicrobial agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

Anti-Mycobacterium avium activity of quinolones: in vitro activities

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

In vitro activity of AT-4140 against clinical bacterial isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

Susceptibility of Xanthomonas maltophilia to six quinolones and study of outer membrane proteins in resistant mutants selected in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

In vitro activity of sparfloxacin and other antimicrobial agents against genital pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

Comparative in-vitro susceptibilities of Pseudomonas aeruginosa, Xanthomonas maltophilia, and Pseudomonas spp. to sparfloxacin (CI-978, AT-4140, PD131501) and reference antimicrobial agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

In vitro Activity of Sparfloxacin and Six Reference Antibiotics against Gram-Positive Bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

In vitro activity of nine fluoroquinolone antibiotics against 200 strains of enterococci

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

In vitro and in vivo activities of sparfloxacin, other quinolones, and tetracyclines against Chlamydia trachomatis

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

In-vitro antimicrobial susceptibility of Rhodococcus equi

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

Development of resistance in Pseudomonas aeruginosa to imipenem, norfloxacin, and ciprofloxacin during therapy: proof provided by typing with a DNA probe

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

Activity of CP99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

Emergence of ciprofloxacin resistance in nosocomial methicillin-resistant Staphylococcus aureus isolates. Resistance during ciprofloxacin plus rifampin therapy for methicillin-resistant S aureus colonization

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

In vitro Activity of Sparfloxacin (CI-978), a New Broad-Spectrum Fluoroquinolone

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

In vitro susceptibilities of Coxiella burnetii, Rickettsia rickettsii, and Rickettsia conorii to the fluoroquinolone sparfloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

In vitro activity of the new difluorinated quinolone sparfloxacin (AT-4140) against Mycobacterium tuberculosis compared with activities of ofloxacin and ciprofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

Antimycobacterial spectrum of sparfloxacin and its activities alone and in association with other drugs against Mycobacterium avium complex growing extracellularly and intracellularly in murine and human macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

In vitro susceptibilities of Mycoplasma genitalium to antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

Comparative in-vitro activity of new quinolones against clinical isolates and resistant mutants

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

Comparative in vitro activities of newer quinolones against Pseudomonas species and Xanthomonas maltophilia isolated from patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

In vitro activity of sparfloxacin (CI-978; AT-4140) against clinical isolates from cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

In vitro activity of sparfloxacin, ciprofloxacin, ofloxacin, and other antibiotics against bloodstream isolates of gram-positive cocci.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

In vitro susceptibility of Brucella melitensis to antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

In vitro activity of sparfloxacin (AT-4140 and CI-978), a new quinolone antimicrobial agent, against Haemophilus and gram-positive cocci

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

Comparative in vitro activities of sparfloxacin (CI-978; AT-4140) and other antimicrobial agents against staphylococci, enterococci, and respiratory tract pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

Comparison of activities of fluoroquinolones in murine macrophages infected with Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

In vitro activity of sparfloxacin and three other fluoroquinolones against methicillin-resistantStaphylococcus aureus andStaphylococcus epidermidis

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

Antimicrobial activity of DV-7751a, a new fluoroquinolone

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

In vitro studies with five quinolones: evidence for changes in relative potency as quinolone resistance rises

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications for therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

Comparative in vitro antibacterial activity of sparfloxacin (AT-4140; RP 64206), a new quinolone

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

Decreased sensitivity of Neisseria gonorrhoeae to quinolone compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

In vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to sparfloxacin and PD 127391.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

In vitro activities of three of the newer quinolones against anaerobic bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

Susceptibility of Mycobacterium kansasii to ofloxacin, sparfloxacin, clarithromycin, azithromycin, and fusidic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

In vitro susceptibility of Mycobacterium avium complex to the new fluoroquinolone sparfloxacin (CI-978; AT-4140) and comparison with ciprofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

Drug resistance and adherence to human intestines of enteroaggregative Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

In vitro activity of 43 antimicrobial agents tested against ampicillin-resistant enterococci and gram-positive species resistant to vancomycin.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

In-vitro activity of quinolones and macrolides against mycobacteria.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2896%2900121-6

7 January 2021

10.1016/S0732-8893(96)00121-6

Identifiers

DOI

1 reference

16 August 2017

1 reference